<DOC>
	<DOC>NCT01556360</DOC>
	<brief_summary>The purpose of this study is to describe bone status on patients with genetic hemochromatosis, at diagnostic time and his evolution under treatment.</brief_summary>
	<brief_title>Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study</brief_title>
	<detailed_description>Bone diseases have been recognized recently as complications of genetic hemochromatosis. Further studies are needed to describe the role of iron in bone injuries. The purpose of this study is to describe bone status on patients with genetical hemochromatosis, at diagnostic time and his evolution under treatment.</detailed_description>
	<mesh_term>Hemochromatosis</mesh_term>
	<criteria>Patients between 18 and 80 years C282 homozygosity corticosteroids during the last 3 months following treatments during the last 6 months : anabolic steroids, growth hormone, hormone therapy for menopause, tibolone, raloxifene. following treatments during inclusion or in the last 6 month : teriparatide, parathormone, fluor, strontium ranelate, biphosphonate. cancer or evolutionary hemopathy (including monoclonal gammopathy) pregnancy at inclusion time treated osteoporosis patient in wich follow up seems hard inclusion in another study incompatible with this one</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>genetic hemochromatosis</keyword>
	<keyword>Iron overload</keyword>
	<keyword>C282 homozygosity</keyword>
</DOC>